Docetaxel, identified by its CAS number 114977-28-5, stands as a cornerstone in modern cancer chemotherapy. This potent pharmaceutical raw material, a member of the taxane family, is crucial for developing effective treatments against a range of aggressive cancers. For pharmaceutical procurement specialists, understanding the nuances of Docetaxel API, including its CAS number and high purity requirements, is essential for ensuring product quality and regulatory compliance.

As a critical component in advanced cancer therapies, Docetaxel API is valued for its ability to stabilize microtubules, thereby inhibiting cell division and halting cancer cell proliferation. Its effectiveness spans across various cancer types, including breast, prostate, lung, and gastric cancers, making it a highly sought-after compound in pharmaceutical manufacturing. The availability of high-purity docetaxel powder, typically exceeding 99% purity, is non-negotiable for meeting stringent pharmaceutical standards.

When considering procurement, the docetaxel CAS 114977-28-5 price is a significant factor for manufacturers aiming to balance cost-effectiveness with product quality. Securing a reliable docetaxel supplier that can guarantee consistent purity, timely delivery, and competitive pricing is paramount. Companies specializing in pharmaceutical raw materials play a vital role in this supply chain, ensuring that the necessary quantities of this life-saving API are readily available.

The journey from sourcing Docetaxel API to its incorporation into finished pharmaceutical products involves rigorous quality control and adherence to Good Manufacturing Practices (GMP). This commitment ensures that the final drug formulation is safe and effective for patient use. By focusing on the critical aspects of Docetaxel API, including its CAS number, purity, and reliable sourcing, the pharmaceutical industry can continue to advance cancer treatment options and improve patient outcomes.